IDYA IDEAYA Biosciences
- 38.450
- -2.930-7.08%
- 38.450
- 0.0000.00%
IDEAYA Biosciences News
IDEAYA Biosciences Inc: Darovasertib was generally well tolerated No serious drug-related adverse events
IDEAYA Biosciences Inc: Darovasertib was generally well tolerated No serious drug-related adverse events
Express News | IDEAYA Biosciences Inc: About 67% Eye Preservation Rate With Darovasertib Monotherapy Neoadjuvant Uveal Melanoma Treatment
Express News | IDEAYA Biosciences Inc: Darovasertib Was Generally Well Tolerated With No Drug-Related Serious Adverse Events
IDEAYA Biosciences Announces 2024 Asco Oral Presentation Summary Results of the Investigator-Sponsored Phase 2 Study of Darovasertib for Neo-Adjuvant Uveal Melanoma
IDEAYA Biosciences Announces 2024 Asco Oral Presentation Summary Results of the Investigator-Sponsored Phase 2 Study of Darovasertib for Neo-Adjuvant Uveal Melanoma
Express News | IDEAYA Biosciences Announces Abstract Summary Results of Asco 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences(IDYA.US) Officer Sells US$7.4 Million in Common Stock
$IDEAYA Biosciences(IDYA.US)$ Officer Hata Yujiro S sold 175K shares of common stock on May 14, 15, 16, 2024 at an average price of $42.2702 for a total value of $7.4 million.Source: Announcement What
Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing
Yujiro S Hata, Director, President and CEO, on May 14, 2024, sold 175,000 shares in Ideaya Biosciences (IDYA) for $7,397,291. Following the Form 4 filing with the SEC, Hata has control over a total of
IDEAYA Biosciences Is Maintained at Buy by Goldman Sachs
IDEAYA Biosciences Is Maintained at Buy by Goldman Sachs
Goldman Sachs: Maintains IDEAYA Biosciences (IDYA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $53.00 to $46.00.
Goldman Sachs: Maintains IDEAYA Biosciences (IDYA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $53.00 to $46.00.
Goldman Sachs Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $46
Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences with a Buy and lowers the price target from $53 to $46.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Just Slashed This Year's Revenue Estimates By 28%
The analysts covering IDEAYA Biosciences, Inc. (NASDAQ:IDYA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This r
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Buy Rating Affirmed for IDEAYA Biosciences Amid Promising Clinical Updates and Pipeline Catalysts
Unveiling 5 Analyst Insights On IDEAYA Biosciences
In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:IDYA), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates t
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target
Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $52 price target.
IDEAYA Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 23.77% Wedbush → $52 Reiterates Outperform → Outperform 03/21/2024 42.81% Citigroup $40 → $60 M
Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating
IDEAYA Biosciences (IDYA) has an average rating of Buy and price targets ranging from $50 to $60, according to analysts polled by Capital IQ.
IDEAYA Biosciences (IDYA) Receives a Buy From Wedbush
Buy Rating Affirmed: IDEAYA Biosciences' Promising Pipeline and Strong Financial Position
Analysis
Price Target
No Data
